Literature DB >> 11949635

Mutations of Chk2 in primary hematopoietic neoplasms.

Akira Hangaishi, Seishi Ogawa, Ying Qiao, Lili Wang, Noriko Hosoya, Koichiro Yuji, Yoichi Imai, Kengo Takeuchi, Shuichi Miyawaki, Hisamaru Hirai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11949635     DOI： 10.1182/blood.v99.8.3075

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations.

Authors:  Hanna Janiszewska; Aneta Bak; Maria Pilarska; Marta Heise; Anna Junkiert-Czarnecka; Małgorzata Kuliszkiewicz-Janus; Małgorzata Całbecka; Bozena Jaźwiec; Dariusz Wołowiec; Kazimierz Kuliczkowski; Olga Haus
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

2.  Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1.

Authors:  Sang Soo Kim; Liu Cao; Cuiling Li; Xiaoling Xu; L Julie Huber; Lewis A Chodosh; Chu-Xia Deng
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

3.  Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

Authors:  Daphne W Bell; Sang H Kim; Andrew K Godwin; Taryn A Schiripo; Patricia L Harris; Sara M Haserlat; Doke C R Wahrer; Christopher A Haiman; Mary B Daly; Kristin B Niendorf; Matthew R Smith; Dennis C Sgroi; Judy E Garber; Olufunmilayo I Olopade; Loic Le Marchand; Brian E Henderson; David Altshuler; Daniel A Haber; Matthew L Freedman
Journal:  Int J Cancer       Date:  2007-12-15       Impact factor: 7.396

Review 4.  The genetics of familial lymphomas.

Authors:  Rina Siddiqui; Kenan Onel; Flavia Facio; Kenneth Offit
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

5.  The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis.

Authors:  L B Koppert; M Schutte; M Abbou; H W Tilanus; W N M Dinjens
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

Review 6.  The cell cycle checkpoint inhibitors in the treatment of leukemias.

Authors:  A Ghelli Luserna di Rora'; I Iacobucci; G Martinelli
Journal:  J Hematol Oncol       Date:  2017-03-29       Impact factor: 17.388

Review 7.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.

Authors:  Lenka Stolarova; Petra Kleiblova; Marketa Janatova; Jana Soukupova; Petra Zemankova; Libor Macurek; Zdenek Kleibl
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

8.  P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.

Authors:  Nitesh P Shirsath; Sonal M Manohar; Kalpana S Joshi
Journal:  Mol Cancer       Date:  2012-10-18       Impact factor: 27.401

9.  Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.

Authors:  Ondrej Havranek; Petra Kleiblova; Jan Hojny; Filip Lhota; Pavel Soucek; Marek Trneny; Zdenek Kleibl
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.